NEW YORK, June 12, 2013 /PRNewswire/ --
Today, Wall Street Reports announced new research reports highlighting AmerisourceBergen Corporation (NYSE: ABC), Zoetis Inc. (NYSE: ZTS), AstraZeneca PLC (NYSE: AZN), Cardinal Health, Inc. (NYSE: CAH) and Sanofi (NYSE: SNY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
AmerisourceBergen Corporation Research Report
On June 3, 2013, AmerisourceBergen Corporation (AmerisourceBergen) announced that it has completed the divestiture of its Canadian pharmaceutical distribution business, AmerisourceBergen Canada Corporation (ABCC). The business has been sold to Kohl & Frisch Limited, a Canadian-owned national full-line distributor. AmerisourceBergen will retain its Canadian specialty business. In the quarter ended March 31, 2013, the Company recorded an estimated loss on sale and other impairment charges of $161.7 million, which is subject to post closing purchase price adjustments. The Company expects to finalize these adjustments with Kohl & Frisch Limited during the quarter ending September 30, 2013. The Full Research Report on AmerisourceBergen Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at [http://www.wsreports.com/r/full_research_report/2df0_ABC]
--
Zoetis Inc. Research Report
On June 3, 2013, Zoetis Inc. (Zoetis) and American Humane Association announced the beginning of the pilot trial of a groundbreaking research study called, The Canines and Childhood Cancer (CCC): Examining the Effects of Therapy Dogs with Childhood Cancer Patients and their Families. The CCC study will examine specific health effects that animal-assisted therapy may have for children with cancer and their families. Vanessa Mariani, Director Academic & Professional Affairs for Zoetis said, "We are very encouraged that the Canines and Childhood Cancer study will be a solid step in that direction - we have already seen enthusiasm for this type of therapy in several hospitals and we hope our data will allow for more regular adoption of Animal Assisted Therapy." The patient population for the pilot will be children aged 3 through 11 years who are newly diagnosed with acute lymphoblastic leukemia. The Full Research Report on Zoetis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at [http://www.wsreports.com/r/full_research_report/7e28_ZTS]
--
AstraZeneca PLC Research Report
On June 4, 2013, AstraZeneca PLC (AstraZeneca) announced top-line results from OSKIRA-2 and OSKIRA-3, the remaining pivotal Phase III clinical trials investigating fostamatinib, the first oral spleen tyrosine kinase (SYK) inhibitor in development as an oral treatment for rheumatoid arthritis (RA). Briggs Morrison, MD, Executive Vice President of Global Medicines Development and Chief Medical Officer, said: "The results of the late stage trials did not measure up to the promising results we saw earlier in development. We remain committed to the search for new treatments for patients with rheumatic and inflammatory diseases with Phase II compounds in rheumatoid arthritis and lupus and Phase III compounds in gout and psoriasis." AstraZeneca has decided not to proceed with regulatory filings for fostamatinib. AstraZeneca will return the rights to the compound to Rigel Pharmaceuticals which will decide whether it will continue the ongoing studies and pursue regulatory filings. The Full Research Report on AstraZeneca PLC - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at [http://www.wsreports.com/r/full_research_report/02c7_AZN]
--
Cardinal Health, Inc. Research Report
On May 23, 2013, Cardinal Health, Inc. (Cardinal Health) announced that it has received the National Business Group on Health (NBGH) Platinum Best Employers for Healthy Lifestyles award for its ongoing commitment to promoting a healthy workplace and encouraging employees to maintain healthy lifestyles. "Since the launch of our Healthy Lifestyles program, we've worked to provide the tools and resources our employees need to engage in a healthy approach to living," said Carole Watkins, Chief Human Resources Officer at Cardinal Health. "We're pleased to be recognized by the National Business Group on Health for our success in doing so, and we're proud to be among companies building best-in-class programs." The Full Research Report on Cardinal Health, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at [http://www.wsreports.com/r/full_research_report/ee38_CAH]
--
Sanofi Research Report
On June 4, 2013, Sanofi announced that Connect & Coach has been selected as the winning solution of the 2013 Data Design Diabetes (DDD) Innovation Challenge - Prove it! Sanofi US will award Connect & Coach™ $100,000 to further develop its novel, data-driven solution to help improve health outcomes for people living with diabetes. Designed for the retail supermarket or pharmacy setting, Connect & Coach is the first hybrid clinical and consumer application for Registered Dietitians and Certified Diabetes Educators to help educate the diabetes community. Dennis Urbaniak, Vice President, U.S. Diabetes Patient Centered Unit, Sanofi US and DDD Judge said, "The Connect & Coach solution embodies the vision of Data Design Diabetes to find forward-thinking solutions that may help today's 26 million Americans who are living with diabetes." The Full Research Report on Sanofi - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at [http://www.wsreports.com/r/full_research_report/26eb_SNY]
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquires, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE Wall Street Reports